Project Grant R01CA297470
Award Date
12/11/24
Completion Date
11/30/29
Dollars Obligated
$582K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a for-profit limited liability company based in Baltimore, Maryland. The award's objective is to develop a prototype web/cloud-based quantitative SPECT reconstruction software system to enable precise quantitative imaging and dosimetry for emerging radiopharmaceutical cancer therapies, particularly those utilizing...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop an innovative, quantitative radiation imaging tool that allows researchers and radiopharmaceutical developers to visualize the spatial distribution and isotopic composition of targeted alpha therapy molecules. The $811,503 award, with a period of...
The U.S. National Cancer Institute (NCI) awarded a $898,497 Phase II Small Business Innovation Research (SBIR) grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Radiopharmaceutical Imaging and Dosimetry, LLC (RAPID). The funding will support the development of a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. The key objectives of the project are to: 1) establish a library of microscale radiation dose...
This $497,870 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of genetically-encoded molecular imaging techniques to non-invasively monitor and track genome-edited immune cells, such as CAR-T cells, in vivo. The project aims to engineer mammalian cells to express bacterial metallophore transport proteins that can bind radionuclide-labeled probes, enabling real-time PET imaging and tracking of the...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to M3D, Inc. will develop a novel gamma-ray radiation imager for image-guided tumor diagnostics. The goal is to create a system capable of rapidly and accurately detecting gamma-ray emitting radiotracers used to identify the location of lymph nodes and tumor drainage during cancer surgical procedures. The project will characterize the design parameters of the...
The National Cancer Institute awarded a $632,300 Project Grant (CFDA 93.396 - Cancer Biology Research) to Carnegie Mellon University to develop an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system for cancer research. The award period is from April 1, 2025 to March 31, 2030. The proposed system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging of the tumor microenvironment at subcellular...
This $644,622 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalization approaches. The key products and services to be delivered under this grant include: 1) Developing a novel method for bone marrow dosimetry by coupling macro/micro Monte Carlo modeling with imaging data; 2) Building predictive models to estimate...
This $666,670 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop innovative scan protocols that combine positron emission tomography (PET) and spectral computed tomography (CT) to enhance cancer diagnosis and quantification capabilities. The key objectives are to: 1) Develop spectral CT protocols and processing pipelines to generate dynamic iodine maps and perfusion data; 2) Integrate the spectral...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" program (CFDA 93.286), is funding the development of a rapid, inexpensive microfluidics-based approach for on-demand production of radiopharmaceuticals. The $1,149,264 award, with a project period from March 1, 2025 to February 28, 2029, aims to reduce barriers associated with...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $627,573 Project Grant to the Research Institute at Nationwide Children's Hospital to develop innovative methods for optimizing alpha-emitter radioligand therapy (a-RLT) for the treatment of neuroendocrine tumors. The key objectives are to: 1) investigate the role of superoxide dismutation in mitigating tubular DNA damage following a-RLT treatment, and 2) identify a-RLT dosing regimens that maximize tumor responses...